Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for ...

Anzupgo is the first topical pan-Janus kinase (JAK) inhibitor to be approved in Switzerland specifically for moderate to ...

The Swiss therapeutic products agency has begun reviewing another anti-Covid 19 vaccine in the rolling submission procedure. Swissmedic said the United States pharmaceutical company Pfizer ...

At the OCT DACH conference, experts shared how EU laws, digitalisation, and more, are impacting trials in the DACH region and ...

ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Swissmedic has granted temporary marketing ...

Just over a year ago, New Zealand customs officials started to intercept batches of injectable medications labelled Fitaro ...

Vortioxetine, which is already approved by the FDA in the U.S. and Swissmedic, has the crucial ability to cross the ...

Thanks to our increase in capacity and ongoing launch expansion. In the third quarter, CARVYKTI became commercially available ...

NOT INTENDED FOR UK MEDIA LEO Pharma A/S, a global leader in medical dermatology, today announced that Swissmedic, Switzerland's national regulatory agency for approving and overseeing therapeutic ...

Announced plans for new, state-of-the-art cell therapy R&D facility in Philadelphia Cash and cash equivalents, and time deposits of $1.2 billion, as of September 30, 2024, which Legend Biotech ...

"Swissmedic approval further demonstrates our promise to deliver transformational medicines for patients with serious diseases in our areas of focus," said Emmanuelle Lecomte Brisset, Senior Vice ...

Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT TrialSAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Travere ...